ARLINGTON, Texas, Aug. 10 -- The University of Texas at Arlington issued the following news release:
New research from The University of Texas at Arlington helps explain a longstanding puzzle in melanoma treatment: why continuous targeted therapy performed better than planned on-and-off treatment schedules in clinical trials, despite promising laboratory studies of intermittent dosing.
In 2026, an estimated 112,000 new melanoma cases will be diagnosed in the United States, and approximately 8,510 people will die from the disease, according to the American Cancer Society. To improve treatment for melanoma and other cancers, researchers analyzed different dosing strategies, finding that adjusting treatment schedules over time may offer a mo...